1620 Investment Advisors’s Astria Therapeutics ATXS Stock Holding History

1620 Investment Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,000	Closed	-$26.2K	–	662
2025 Q4	$26.2K	Hold	2,000	–	–	0.02%	365
2025 Q3	$14.6K	Hold	2,000	–	–	0.01%	415
2025 Q2	$10.7K	Buy	+2,000	New	+$9.7K	0.01%	450

1620 Investment Advisors's ATXS Position: Q1 2026 in Review

1620 Investment Advisors sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 2,000 shares — an estimated $26.2K sold.

1620 Investment Advisors first reported a position in ATXS in Q2 2025 and held it in 3 quarters. The position peaked at $26.2K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

1620 Investment Advisors reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
1620 Investment Advisors sold 2,000 Astria Therapeutics shares in Q1 2026, an estimated $26.2K.
1620 Investment Advisors first reported a position in Astria Therapeutics in Q2 2025 and held it in 3 quarters.
1620 Investment Advisors's Astria Therapeutics position peaked at $26.2K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on 1620 Investment Advisors's 13F filing for Q1 2026, filed 13 May 2026.